Actinogen is a neurotherapeutics developer realizing a revolutionary therapy so neurology patients and their families can live their best lives
The Actinogen phase 2b/3 Alzheimer’s disease trial is now recruiting
Latest Summary Corporate Presentation
View PresentationThe Xanamem® Pipeline
Diseases to be studied
Phase 2 placebo-controlled trials
Outlook
Biomarker analysis in patients with mild AD
Cognitive benefit in patients with early stages of AD
Pivotal trials focused on cognitive enhancement
Diseases to be studied
Phase 2 placebo-controlled trials
Outlook
Depression and cognitive impairment
Pivotal trials assessing both depression and cognitive impairment
Diseases to be studied
Phase 2 placebo-controlled trials
Outlook
Proof of concept in adolescent and young adult males
Pending alternative funding e.g. partnerships or grants
The Actinogen phase 2b/3 Alzheimer’s disease trial is now recruiting
Latest News
View all news
Latest Summary Corporate Presentation
View Presentation05 Feb 2025 | PR Newswire | |
05 Feb 2025 | Hobart Mercury | |
24 Jan 2025 | Actinogen | |
12 Jan 2025 | Actinogen | |
06 Jan 2025 | Daily Mail Online |
Stay updated
If you would like to receive our latest news and updates, you can join our email distribution list. Simply register your details.
Investors View Investor Centre
ASX Announcements
View all ASX AnnouncementsAnalyst REPORTS
-
15 Oct 2024
Edison Investment Research update
Actinogen Medical – A$11.1m capital raise completed -
07 Oct 2024
Edison Investment Research update
Actinogen Medical – Funding in place to complete XanaMIA Phase IIb -
27 Aug 2024
Edison Investment Research update
Actinogen Medical – Further positive XanaCIDD results on depression -
22 Aug 2024
Edison Investment Research update
Actinogen Medical – XanaCIDD data narrow the focus in depression